155 related articles for article (PubMed ID: 35383291)
21. Droplet digital polymerase chain reaction for detection and quantification of cell-free DNA TP53 target somatic mutations in oral cancer.
Lin LH; Cheng HW; Liu CJ
Cancer Biomark; 2022; 33(1):29-41. PubMed ID: 34366328
[TBL] [Abstract][Full Text] [Related]
22. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
23. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.
Kantorova B; Malcikova J; Smardova J; Pavlova S; Trbusek M; Tom N; Plevova K; Tichy B; Truong S; Diviskova E; Kotaskova J; Oltova A; Patten N; Brychtova Y; Doubek M; Mayer J; Pospisilova S
Tumour Biol; 2015 May; 36(5):3371-80. PubMed ID: 25527155
[TBL] [Abstract][Full Text] [Related]
24.
Forgione MO; McClure BJ; Page EC; Yeung DT; Eadie LN; White DL
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35323988
[TBL] [Abstract][Full Text] [Related]
25. TP53 in Biology and Treatment of Osteosarcoma.
Synoradzki KJ; Bartnik E; Czarnecka AM; Fiedorowicz M; Firlej W; Brodziak A; Stasinska A; Rutkowski P; Grieb P
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503094
[TBL] [Abstract][Full Text] [Related]
26. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
Venugopal S; Loghavi S
Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
[TBL] [Abstract][Full Text] [Related]
27. Towards fast and inexpensive molecular diagnostic: the case of TP53.
Jiang T; Minunni M; Mascini M
Clin Chim Acta; 2004 May; 343(1-2):45-60. PubMed ID: 15115677
[TBL] [Abstract][Full Text] [Related]
28. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Daver NG; Maiti A; Kadia TM; Vyas P; Majeti R; Wei AH; Garcia-Manero G; Craddock C; Sallman DA; Kantarjian HM
Cancer Discov; 2022 Nov; 12(11):2516-2529. PubMed ID: 36218325
[TBL] [Abstract][Full Text] [Related]
29. p53 Dysregulation in Breast Cancer: Insights on Mutations in the
Steffens Reinhardt L; Groen K; Xavier A; Avery-Kiejda KA
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373225
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer.
Ghojazadeh M; Somi MH; Naseri A; Salehi-Pourmehr H; Hassannezhad S; Hajikamanaj Olia A; Kafshdouz L; Nikniaz Z
Middle East J Dig Dis; 2022 Jul; 14(3):335-345. PubMed ID: 36619267
[No Abstract] [Full Text] [Related]
31. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
Id Said B; Kim H; Tran J; Novokmet A; Malkin D
Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
[TBL] [Abstract][Full Text] [Related]
32. Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors.
Treger TD; Chagtai T; Butcher R; Cresswell GD; Al-Saadi R; Brok J; Williams RD; Roberts C; Luscombe NM; Pritchard Jones K; Mifsud W
Transl Oncol; 2018 Dec; 11(6):1301-1306. PubMed ID: 30172241
[TBL] [Abstract][Full Text] [Related]
33. Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Schuyer M; Berns EM
Mol Cell Endocrinol; 1999 Sep; 155(1-2):143-52. PubMed ID: 10580847
[TBL] [Abstract][Full Text] [Related]
34. TP53 Mutation Estimation Based on MRI Radiomics Analysis for Breast Cancer.
Sun K; Zhu H; Chai W; Yan F
J Magn Reson Imaging; 2023 Apr; 57(4):1095-1103. PubMed ID: 35771720
[TBL] [Abstract][Full Text] [Related]
35. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P; Prade N; Lagarde S; Cabarrou B; Largeaud L; Plenecassagnes J; Luquet I; De Mas V; Filleron T; Cassou M; Sarry A; Fornecker LM; Simand C; Bertoli S; Recher C; Delabesse E
PLoS One; 2020; 15(10):e0238795. PubMed ID: 33001991
[TBL] [Abstract][Full Text] [Related]
36. The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
Ramelow J; Brooks CD; Gao L; Almiman AA; Williams TM; Villalona-Calero MA; Duan W
BMC Cancer; 2020 Aug; 20(1):738. PubMed ID: 32770960
[TBL] [Abstract][Full Text] [Related]
37. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
38. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H
J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005
[TBL] [Abstract][Full Text] [Related]
39. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
[TBL] [Abstract][Full Text] [Related]
40. Suppression of apoptosis and clonogenic survival in irradiated human lymphoblasts with different TP53 status.
Schäfer J; Bachtler J; Engling A; Little JB; Weber KJ; Wenz F
Radiat Res; 2002 Dec; 158(6):699-706. PubMed ID: 12452772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
